CHENGDU, China, April 22, 2015 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced that the Company will hold its Annual Meeting of Stockholders for fiscal year ended June 30, 2014 at 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3, Renmin Road South, Chengdu City, Sichuan Province, P. R. China, 610041, at 9:00 AM (local time in Chengdu, China) on Monday, May 25, 2015 (the "Meeting Date"), a.k.a 9:00 PM (Eastern Standard Time) on Sunday, May 24, 2015. You may attend the meeting in person or telephonically by dialing in (+1) 712-432-0080, access code 512917#. The Company is holding the meeting for the following purposes: 1) To elect members of the Board of Directors; 2) To approve and ratify the re-appointment of Paritz & Company, P.A. as the Company's independent accountants to audit the Company's financial statements as at June 30, 2015 and for the fiscal year then ending; and 3) To transact such other business as may properly come before the meeting and any postponement or adjournment thereof.
Shareholders may vote via internet at http://www.empirestock.com/proxy/tpi.html following the instructions therein; or simply sign the proxy card where required, note the number of shares you own and if you will attend the meeting in person, and return the card in the envelope provided to us at the address first written above.
Headquartered at Chengdu, China, with Dr. Guoqing Jiang as Company's Chairman and CEO, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. The production of TPI's new Qionglai manufacturing facility (QLF) is ongoing after receiving the GMP certification by SFDA (Certification No.: SC20140067, valid till July 1, 2020) according the latest GMP standards. For more information about TPI, please visit: http://www.tianyinpharma.com.
The TPI-Buchang Strategic Alliance
TPI and Buchang Pharmaceutical Co., Ltd. ("Buchang Pharma", http://www.bloomberg.com/profiles/companies/SHPHRZ:CH-shandong-buchang-pharmaceuticals-co-ltd in early 2015 established Tianyin-Buchang Strategic Alliance (the "Alliance") to synergize and accelerate the growth of the Company, boosting the mTCM franchise focusing on its cardiovascular revenue driver Gingko Mihuan (GMOL). The Alliance is based upon TPI's newly completed Qionglai Tianyin Facility (QLF) with the expanded production capacities in mTCM pre-extraction, purification and formulation manufacturing, which is planned to synergize the current sales coverage with the Buchang Pharma's network resources (more than 15,000 hospitals nationwide) to enhance TPI's product portfolio focusing on TPI's lead revenue driver GMOL. The integration of the sales network of TPI-Buchang Pharma platform is currently on going.
About Buchang Pharma
Buchang Pharmaceutical Co., Ltd., headquartered in Xi'an, established in 1993, by Prof. Buchang Zhao is a pre-IPO targeting going public on Shanghai main board in 2015, (Citic Securities, 2015) pharmaceutical enterprise focusing on research, development, manufacturing and distribution of medicines and health care products in China. Buchang Pharma is one of the leading pharmaceutical companies in China and specializes in cardio-cerebral vascular (CCV) drugs and mTCM research and development. Within its comprehensive portfolio of over 60 nationally reimbursed products, Buchang Pharma's Naoxintong Capsules, Yinxin Granules and Danhong Injection are three proprietary cardiovascular products that delivered $1.1 billion total annual sales in 2013. Listed in the prospectus of the Company, Buchang's cardiovascular franchise ranked No.1, making up 8.1% of the total of China's CCV market in 2012. With more than 10,000 professional sales representatives covering 15,000 hospitals and 130,000 pharmacies, Buchang Pharma has established a comprehensive network in China's large healthcare industry. The annual sales of Buchang Pharma were RMB 3.6 billion (approximately $510 million) in 2008, RMB 5.2 billion (approximately $560 million) in 2009, RMB 6.5 billion (approximately $1 billion) in 2010 and RMB 8.6 billion (approximately $1.4 billion) in 2013, more than doubled within 5 years. For additional information on Buchang Pharma in English, please click http://www.buchang.com/english/about.asp; or, in Chinese, http://www.buchang.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
Tel: +86-28-8551-6696 (Chengdu, China)
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
SOURCE Tianyin Pharmaceutical Co., Inc.